筋骨草总黄酮对慢性血清病肾炎大鼠自由基损伤的影响

目的:探讨筋骨草总黄酮对慢性血清病肾炎大鼠的治疗作用及其作用机制。方法:采用大鼠改良慢性血清病肾炎模型,于造模第5周末检测尿蛋白,将尿蛋白阳性者随机分为模型组、雷公藤多苷组、筋骨草总黄酮组,另设正常对照组。于造模第6周起开始给药,6周后,测定各组大鼠的24h尿蛋白定量、血生化和血清中SOD、MDA的含量,光镜下观察肾组织病理形态学变化。结果:与模型组相比,筋骨草总黄酮组可显著降低尿蛋白[(38.91±10.62)mg/24hvs(18.28±8.07)mg/24h,P<0.01],且可明显升高TP、SOD,降低BUN、Scr、TG、TC、MDA(P<0.05或P<0.01);形态学观察也显示筋骨草总黄酮组较模型组损害减轻[(0.196±0.035)vs(0.304±0.059),P<0.01]。而筋骨草总黄酮组与雷公藤多苷组相比,可明显提高SOD活性[(0.379±0.042)U/mlvs(0.327±0.063)U/ml,P<0.05],显著降低TC[(1.63±0.23)mmol/Lvs(1.95±0.37)mmol/L,P<0.05]、MDA含量[(4.773±0.675)U/mlvs(6.526±2.727)U/ml,P<0.05];且筋骨草总黄酮组ALT明显低于雷公藤多苷组[(57.60±8.09)U/Lvs(83.40±11.53)U/L,P<0.01]。结论:筋骨草总黄酮对慢性血清病肾炎大鼠有较好的治疗作用,而提高SOD活性、降低MDA、抑制脂质过氧化反应、减轻自由基损伤等可能是其治疗作用机制之一。

720肾炎颗粒对慢性血清病性肾炎模型大鼠血浆ET-1的影响

目的:研究720肾炎颗粒治疗慢性肾炎的作用机制。方法:将雄性SD大鼠40只,随机分为正常组、模型组、泼尼松组、中药组,每组10只,以牛血清清蛋白皮下及静脉注射建立慢性血清病性肾炎模型,观察各组大鼠血浆内皮素(ET-1)、β2微球蛋白(β2-MG)水平及肾脏病理变化情况。结果:与模型组比较,中药组大鼠血浆β2-MG含量降低(P<0.01)、ET-1含量降低(P<0.05)。结论:720肾炎颗粒能够降低慢性血清病性肾炎模型大鼠血浆ET-1和β2-MG水平,可保护肾小球滤过功能。

丹酚酸B对慢性血清病肾炎大鼠肾脏保护作用的研究

目的探讨丹酚酸B对慢性血清病肾炎大鼠模型的影响及肾脏保护作用。方法通过改良后的免疫学方法制备慢性血清病肾炎大鼠模型,造模成功后给予丹酚酸B(100,50 mg·kg^(-1))连续灌胃5周,探讨丹酚酸B对慢性血清病肾炎大鼠肾脏指数、24h尿蛋白、血清肌酐(Scr)、尿素氮(BUN)、白蛋白(ALB)、总蛋白(TP)、总胆固醇(TC)、甘油三酯(TG)、丙二醛(MDA)、超氧化物歧化酶(SOD)、白细胞介素1α(IL-1α)、白细胞介素10(IL-10)含量的影响。结果与模型组比较,丹酚酸B高、低剂量组可以降低慢性血清病肾炎大鼠肾脏指数(P<0.01);降低24 h尿蛋白排泄量(P<0.05);降低Scr、BUN的含量(P<0.05,P<0.01);降低血清中TC、TG(P<0.05,P<0.01)的含量,升高血清中ALB、TP的含量(P<0.05,P<0.01);降低血清中MDA的含量(P<0.05,P<0.01),升高血清中SOD的含量(P<0.05,P<0.01);降低血清中IL-1α、IL-10的含量(P<0.05,P<0.01)。结论丹酚酸B可以改善慢性血清病肾炎大鼠肾脏功能,调节血脂异常状态,其机制可能与抗脂质过氧化及调节细胞因子平衡有关。

复方肾华治疗大鼠改良慢性血清病肾炎的实验研究

目的 观察复方肾华胶囊对改良大鼠慢性血清病肾炎模型的治疗作用。方法 采取传统大鼠慢性血清病肾炎模型制作方法加上切除大鼠一侧肾脏、隔日饮饲牛血清白蛋白 (BSA)酸化水、腹腔注射大肠杆菌内毒素 (LPS)等措施 ,制作肾炎模型 ,与西药蒙诺作对照 ,观察中药肾华对肾炎大鼠尿蛋白、血生化、凝血指标、肾功能、病理、免疫荧光以及增殖细胞核抗原 (PCNA)表达的作用。结果 肾华胶囊能够显著减轻肾炎大鼠肾脏重量及肾重指数、降低肾炎大鼠尿蛋白、升高血清蛋白、降低胆固醇、甘油三酯、改善肾功能、纠正凝血功能紊乱、减轻肾脏病理改变、减轻免疫荧光变化、减弱PCNA的表达。

肾脏内皮素的定位研究与血浆水平的测定

肾脏内皮素的定位研究与血浆水平的测定目的：探讨内皮素（ＥＴ）与肾小球肾炎的关系。方法：建立改良慢性血清病大鼠系膜增生性肾炎动物模型，采用＾１２５｜Ｉ－ＥＴ放射免疫分析法测定肾炎组与对照组右心血和肾静脉血中ＥＴ－１的水平。应用免疫组化及免疫电镜方法进行...

Serum neopterin levels in children with hepatitis-B-related chronic liver disease and its relationship to disease severity

AIM:To evaluate serum neopterin levels and their correlations with liver function tests and histological grade in children with hepatitis-B-related chronic liver disease. METHODS:The study population comprised 48 patients with chronic active hepatitis B,32 patients with hepatitis-B-related active liver cirrhosis and 40 normal controls. Serum neopterin was measured using an enzyme-linked immunosorbent assay. RESULTS:The mean ± SD serum neopterin levels were 14.2 ± 5.6 nmol/L in patients with chronic hepatitis,20.3 ± 7.9 nmol/L in patients with liver cirrhosis and 5.2 ± 1.4 nmol/L in control group. Serum neopterin levels were signif icantly higher in patients with chronic hepatitis (P = 0.005) and cirrhosis patients (P = 0.008),than in control subjects. Cirrhotic patients had signif icantly higher serum neopterin levels than patients with chronic hepatitis (P = 0.004). There was a positive correlation between serum neopterin levels and alanine aminotransferase levels in patients with chronic hepatitis (r = 0.41,P = 0.004) and cirrhotic patients (r = 0.39,P = 0.005). Positive correlations were detected between serum neopterin levels and inflammatory score in patients with chronic hepatitis (r = 0.51,P = 0.003) and cirrhotic patients (r = 0.49,P = 0.001). CONCLUSION:Our results suggest that serum neopterin levels can be considered as a marker of inflammatory activity and severity of disease in children with hepatitis-B-related chronic liver disease.

Measurement of hepatic functional mass by means of ^(13)C-methacetin and ^(13)C-phenylalanine breath tests in chronic liver disease: Comparison with Child-Pugh score and serum bile acid levels

AIM: To evaluate and compare the clinical usefulness of 13C-phenylalanine and 13C-methacetin breath tests in quantitating functional hepatic mass in patients with chronic liver disease and to further compare these results with those of conventional tests, Child-Pugh score and serum bile acid levels.METHODS: One hundred and forty patients (50 HCV-related chronic hepatitis, 90 liver cirrhosis patients) and 40 matched healthy controls were studied. Both breath test and routine liver test, serum levels of cholic and chenodeoxycholic acid conjugates were evaluated.RESULTS: Methacetin breath test, expressed as 60 min cumulative percent of oxidation, discriminated the hepatic functional capacity not only between controls and liver disease patients, but also between different categories of chronic liver disease patients. Methacetin breath test was correlated with liver function tests and serum bile acids.Furthermore, methacetin breath test, as well as serum bile acids, were highly predictive of Child-Pugh scores. The diagnostic power of phenylalanine breath test was always less than that of methacetin breath test.CONCLUSION: Methacetin breath test represents a safe and accurate diagnostic tool in the evaluation of hepatic functional mass in chronic liver disease patients.